Mcm Polimedica 2 Sp. z o.o.

Warsaw 9 trials 3 recruiting

9 Registered trials

3 Currently recruiting

Organisation

Mcm Polimedica 2 Sp. z o.o.

Location

Warsaw, Poland

Identifier

ORG-100040615

Address

Ul. Belgradzka 52/54, 02-793, Poland

Departments

Allergology
Dzial badan klinicznych
ETG Warszawa
ETG Warszawa .New site location :ul. Wynalazek 4, 02-677 Warszawa . New ID : ORG-100040846
MCM POLIMEDICA
MCM Polimedica/MCM Polimedica 2 Sp. z o.o.
N/A

Clinical trials at this site (9)

Search interface

"A Clinical Study to Evaluate the Effectiveness of Beltavac® with polymerized extract of grass pollen mixture in allergic rhinoconjunctivit… Not authorised

2023-510033-28-00 allergic rhinoconjunctivitis caused due to exposure to 4
Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting

2025-521456-35-00 Mild to moderate asthma 4 2026-04-13
Clinical trial of molnupiravir (MK-4482) in adults who have COVID-19 and are not hospitalized, who are at high risk for serious illness from… Recruiting

2023-507227-36-00 SARS-CoV-2 (COVID-19) infection 5 2025-02-21
Long-term clinical trial of PQ Grass in paediatric subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass poll… Recruiting

2023-508520-36-00 Seasonal allergic rhinitis/rhinoconjunctivitis induced 5 2024-09-06
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Ended

2022-503062-72-00 Chronic Spontaneous Urticaria 4 2023-11-23
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-2) Ended

2023-507665-25-00 Severe Eosinophilic asthma 5 2023-04-25
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) Ended

2022-500881-80-00 Chronic Heart Failure With Reduced Ejection Fraction 5 2021-10-29
An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev… Ended

2022-502361-15-00 Moderate-to-Severe Plaque Psoriasis 5 2019-12-12
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent Exace… Ended

2022-503050-39-00 Moderate to Very Severe Chronic Obstructive Pulmonary D 5 2019-11-12